Public advisory - JAMP Guanfacine XR 1 mg tablets: One lot recalled as some bottles may also contain higher strength tablets Latin America - español Middle East - English USA - Polski USA - español Brazil - Português USA - Français USA - Deutsch USA - Pусский USA - slovenčina USA - čeština
OTTAWA, ON, Dec. 14, 2023 /CNW/ -
Summary
- Product: JAMP Guanfacine XR 1 mg tablets
- Issue: Health products – Product safety
- What to do: Check your or your child's pill bottle to ensure it contains only white, round JAMP Guanfacine XR 1 mg tablets. If it contains any green, oval JAMP Guanfacine XR 4 mg tablets, or if you are unsure, return it to your pharmacy. Your pharmacist will check it and provide you with a replacement if needed. Contact a health care professional immediately if you or your child are experiencing signs and symptoms of overdose (described below).
Affected products
Product |
DIN |
Lot number |
Expiry date |
JAMP Guanfacine XR 1 mg tablets |
02523558 |
GFO2012 |
2024-SE |
Issue
JAMP Pharma Corporation is recalling one lot of JAMP Guanfacine extended release (XR) 1 mg tablets because some bottles may contain JAMP Guanfacine XR 4 mg tablets in addition to the correct strength of 1 mg tablets. Patients taking a 4 mg tablet instead of a prescribed 1 mg tablet will unexpectedly receive a higher dose than intended, which may result in overdose and could pose serious health risks.
JAMP Guanfacine XR is a prescription drug used to treat Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents 6 to 17 years of age.
The 1 mg tablet is white and round with the letters 'GNF' stamped on one side and '1MG' stamped on the other.
The 4 mg tablet is green and oval with the letters 'GNF' stamped on one side and '4MG' stamped on the other.
Signs and symptoms of guanfacine overdose may include hypertension (high blood pressure), hypotension (low blood pressure), bradycardia (slow heartbeat) or abnormal heart rhythms, lethargy (drowsiness/feeling tired), respiratory depression (slowed breathing), or coma (loss of consciousness). It may take up to 24 hours for signs and symptoms of overdose to appear after taking too much of the product. Patients with suspected overdose should consult their health care professional immediately, as they may require monitoring in hospital.
Health Canada is monitoring the company's recall, and its implementation of any necessary corrective and preventative actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified.
What you should do
- Check your or your child's pill bottle of JAMP Guanfacine XR 1 mg tablets to ensure it contains only 1 mg white, round tablets. If it contains any JAMP Guanfacine XR 4 mg green, oval tablets, or if you are unsure, return it to your pharmacy. Your pharmacist will check it and provide you with a replacement if needed.
- Contact a health care professional immediately if you or your child are experiencing signs and symptoms of overdose.
- Contact JAMP Pharma Corporation by calling toll-free at 1-866-399-9091, extension 501, or by email at [email protected], if you have questions about this recall.
- Report any health product-related side effects or complaints to Health Canada.
Additional information for health professionals:
- Health care professionals, such as pharmacists, should check bottles of Guanfacine XR 1 mg tablets before dispensing and report any unusual bottles or other issue to the company and to Health Canada.
Également disponible en français
SOURCE Health Canada (HC)
Media Enquiries: Health Canada, (613) 957-2983, [email protected]; Public Enquiries: (613) 957-2991, 1-866 225-0709, [email protected]
Share this article